Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients

Summary

The purpose of this study is to evaluate the antihypertensive efficacy and tolerability of 8 week treatment with Fimasartan (BR-A-657-K) 20, 60, 120, 240 mg and placebo in patients with mild to moderate essential hypertension and to determine the adequate antihypertensive dosage for later clinical study.

Conditions

• Hypertension

Interventions

DRUG

Fimasartan

Sponsors & Collaborators

• Seoul National University Hospital

  collaborator OTHER

• Samsung Medical Center

  collaborator OTHER

• Asan Medical Center

  collaborator OTHER

• Seoul National University Bundang Hospital

  collaborator OTHER

• The Catholic University of Korea

  collaborator OTHER

• Severance Hospital

  collaborator OTHER

• Yonsei University

  collaborator OTHER

• Cheil General Hospital and Women's Healthcare Center

  collaborator OTHER

• Boryung Pharmaceutical Co., Ltd

  lead INDUSTRY

Principal Investigators

• Byung-Hee Oh, Professor · Seoul National University Hospital

• Jae-Joong Kim, Professor · Asan Medical Center

• Eun-Suk Jeon, Professor · Samsung Medical Center

• Dong-Ju Choi, Professor · Seoul National University Bundang Hospital

• Ki-Bae Seong, Professor · Kangnam ST.Mary's Hospital

• Jong-Won Ha, Professor · Severance Hospital

• Se-Joong Lim, Professor · Yonsei University

• Jeong-Bae Park, Professor · Cheil General Hospital and Women's Healthcare Center

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2007-09-30

Primary Completion

2008-06-30

Completion

2008-06-30

Countries

• South Korea

Study Locations